In this review, an overview of the rationally designed ruthenium-based complexes that were reported to date for breast cancer therapy is presented, with a special emphasis on species that include ligands that were carefully selected for the treatment of hormone receptor positive cancers, either estrogen receptor positive and/or progesterone receptor positive. This evidence concerns the gene PGR and breast cancer.